New Hope for Patients with Advanced Cancer
An experimental pill is showing promise in significantly improving the treatment of cancer, offering new hope to patients with previously incurable forms of the disease. Early-stage trials have revealed encouraging results that could change the landscape of cancer care.
Cancer detected at an early stage can often be treated effectively with standard drugs and surgery. However, when the disease has spread, it becomes much more challenging to manage. Approximately one in five cancer cases are diagnosed at an advanced stage, leaving patients with limited options beyond palliative care, which focuses on symptom relief rather than a cure.
The new drug, known as GRWD5769, may offer a breakthrough for these patients. Designed to be used alongside immunotherapy, which helps the body’s immune system identify and destroy cancer cells, this pill aims to address a major issue: resistance to treatment. Many patients eventually stop responding to immunotherapy, with resistance occurring in two-thirds of cases. GRWD5769 is designed to overcome this challenge.
In the trial, the twice-daily pill was given in combination with immunotherapy to 83 patients suffering from advanced bowel, bladder, lung, cervical, or head and neck cancers. These types of cancer account for around a third of all cases diagnosed in the UK each year.
Results presented at the American Society of Clinical Oncology meeting in Chicago showed that tumours shrank in approximately a third of patients receiving the combination therapy. More than half of those who responded saw their tumours reduced by at least 30 per cent. The pill appeared most effective in lung and bowel cancers, halting disease progression for at least six months in over half of patients, with very few side effects reported.
It also showed benefits for cervical cancer patients, many of whom are diagnosed at a late stage. The drug delayed progression for at least six months in 18 per cent of cases. For liver cancer patients, the tablets halted progression for the same period in nearly a third of cases. In bladder cancer, the rate was 36 per cent, and in head and neck cancers, it was 38 per cent.
The lead investigators on the trial, from The Christie NHS Foundation Trust in Manchester, emphasized that while the early data is promising across several hard-to-treat tumours, further research is needed before the drug can be widely available in clinics.
The combined therapy targets cancer in two distinct but complementary ways. Immunotherapy trains T-cells—disease-fighting cells—to recognize and attack cancer cells. However, in around two-thirds of patients, this treatment fails. The new drug addresses this problem by preventing tumour cells from hiding from the immune system.
The trial is still ongoing, with researchers hoping that the drug will continue to improve outcomes for a range of hard-to-treat cancers.
Dr Samuel Godfrey, research information lead at Cancer Research UK, who was not involved in the trial, welcomed the findings. He said, “It’s unusual to see such outcomes in patients whose cancers have already stopped responding to treatment, particularly across several hard-to-treat cancer types, so these results are encouraging. However, this is still an early-stage study, and larger trials will be needed to determine whether this approach can deliver lasting benefits for patients.”
